Executive Director, CanceRx Foundation, Inc. Managing Director, CanceRx, LLC
Clifford S. Gibbons, JD
Biography
As executive director of CanceRx Foundation, Inc. and President of CanceRx, LLC, Cliff brings over three decades of experience working across the entire R&D cycle of new cancer drugs. His vision is to accelerate the translation of research into impactful cancer therapeutics to improve patient outcomes and investor returns while building teams to achieve results above their imaginations
With over 35 years of experience developing substantial financing for cancer clinical research, Cliff Gibbons is dedicated to driving growth, innovation, and team success in the fight against cancer.
Throughout his career, Cliff has been at the forefront of advancing cancer research and therapeutics. Building on two decades of developing funding for translational clinical research, he inaugurated the National Functional Genomics Center (NFGC) following the publication of The Human Genome Project in 2000, where he strategically assembled an elite consortium of preeminent NCI-Comprehensive Cancer Centers to discover molecular signatures for cancers and accelerate the development of personalized cancer therapeutics.
By 2014, recognizing the enormous cost, limits on federal appropriations, and obstacles in funding successful human clinical trials for new cancer drugs, he launched CanceRx. The CanceRx innovative financing model, developed in collaboration with MIT Sloan School of Management Noble Laureate faculty, bundles projects in a large, diversified long-term bond portfolio to synchronize finance with the speed of science, increase the likelihood of success, and drive impactful patient outcomes.
Achievements & Impact
• Secured over $800m in Federal appropriations for clinical research funding to NFGC partners from 2002 to 2015.
• Instrumental in establishing collaboration between clients Moffitt Cancer Center and Merck & Co. and startup funding for M2Gen, accelerating the discovery of personalized cancer diagnostics and therapeutics.
• Led CanceRx to become a high-impact cancer therapeutics commercialization accelerator, synchronizing finance with the speed of clinical science and FDA approvals.
• Pioneered a financing approach to significantly expand human clinical research, establish robust prevention and surveillance programs, and fast-track the development of advanced therapeutic technologies.
Cliff received his law degree from Florida State University and began his legal career as a prosecutor in Florida. In 1979, he served in the Office of Vice President of the United States. He was later appointed Special Assistant to the President in the White House Office of the United States Trade Representative. After leaving the White House, Cliff headed the international government relations practice with the global law firm of Hogan & Hartson (currently Hogan/Lovells) in Washington, D.C. Prior to launching CanceRx in 2014, he founded Gibbons & Company—Washington, D.C., in 1990, an international government relations and public policy firm in Washington, D.C., which he serves as president. www.Washington-Counsel.com
Biography
With over 35 years of experience developing substantial financing for cancer clinical research, Cliff Gibbons is dedicated to driving growth, innovation, and team success in the fight against cancer.
Throughout his career, Cliff has been at the forefront of advancing cancer research and therapeutics. Building on two decades of developing funding for translational clinical research, he inaugurated the National Functional Genomics Center (NFGC) following the publication of The Human Genome Project in 2000, where he strategically assembled an elite consortium of preeminent NCI-Comprehensive Cancer Centers to discover molecular signatures for cancers and accelerate the development of personalized cancer therapeutics.
By 2014, recognizing the enormous cost, limits on federal appropriations, and obstacles in funding successful human clinical trials for new cancer drugs, he launched CanceRx. The CanceRx innovative financing model, developed in collaboration with MIT Sloan School of Management Noble Laureate faculty, bundles projects in a large, diversified long-term bond portfolio to synchronize finance with the speed of science, increase the likelihood of success, and drive impactful patient outcomes.
Achievements & Impact
• Secured over $800m in Federal appropriations for clinical research funding to NFGC partners from 2002 to 2015.
• Instrumental in establishing collaboration between clients Moffitt Cancer Center and Merck & Co. and startup funding for M2Gen, accelerating the discovery of personalized cancer diagnostics and therapeutics.
• Led CanceRx to become a high-impact cancer therapeutics commercialization accelerator, synchronizing finance with the speed of clinical science and FDA approvals.
• Pioneered a financing approach to significantly expand human clinical research, establish robust prevention and surveillance programs, and fast-track the development of advanced therapeutic technologies.
Cliff received his law degree from Florida State University and began his legal career as a prosecutor in Florida. In 1979, he served in the Office of Vice President of the United States. He was later appointed Special Assistant to the President in the White House Office of the United States Trade Representative. After leaving the White House, Cliff headed the international government relations practice with the global law firm of Hogan & Hartson (currently Hogan/Lovells) in Washington, D.C. Prior to launching CanceRx in 2014, he founded Gibbons & Company—Washington, D.C., in 1990, an international government relations and public policy firm in Washington, D.C., which he serves as president. www.Washington-Counsel.com